



ten23 health completes the superstructure of their new large-scale sterile production facility in Visp, Switzerland

With the initial phase of construction now complete, ten23 will commence with interior construction and hiring of further team members. The sterile manufacturing plant is well on track to be operational in 2024 for global commercial supplies of injectable drugs.

The facility will also be equipped with photovoltaic panels across the whole façade, ensuring optimal use of renewable energy, in line with ten23 health's commitments to the planet.

The facility will have 2 sterile production lines and a total of 5,000 square meters of space to provide an additional 30+ million units/year of fill and finish commercial as well as clinical capacity.

- As previously announced ([News of ten23](#)), ten23 health is expanding into an additional building in Visp with approximately 5,000 square meters of space. The initial phase of construction is complete.
- The expansion will comprise of two additional sterile manufacturing lines using the latest isolator technology, providing optimal sterility assurance levels
- One new filling line will provide significant additional capacity for ready-to-use containers such as syringes and cartridges with an annual capacity of 20 million units, enabling scale-up from ten23's existing production line in Visp.
- A third new manufacturing line with its two lyophilizers will provide new capabilities for filling bulk containers (vials) in liquid and freeze-dried (lyophilized) dosage forms with an estimated 10+ million units.
- The expansions reflect the commitment of ten23 health to our activities in Visp, Valais, Switzerland and the increasing market demand in providing customized expert solutions for our customers and their patients globally.
- The new building's façade will consist of 100% of photovoltaic panels, ensuring to generate energy at the facility, in line with our commitments towards the planet and use of 100% renewable energy.

Visp, September 19, 2022: ten23 health®, a global contract development and manufacturing organization (CDMO) announced today the completion of superstructure of our new sterile manufacturing facility.

The existing FDA- and Swissmedic-inspected facility of ten23 health's swissfillon in Visp already offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and commercial supplies, in close collaboration with ten23 health's development center in Basel.

Our new building, purpose-built for ten23 health, includes two further sterile manufacturing lines. Line 2 will produce large commercial quantities for market supply after regulatory approval of the drug. As a true scaled-up version of our existing filling line 1, the transfer between the lines will be associated with less risk for our biopharma customers. The fill line will be based on latest Isolator technology to increase the safety of the drugs for patients. It will focus on complex products, filled into RTU containers including syringes, cartridges and special primary packaging such as used in specific administration devices for subcutaneous delivery. Fill line 3 will broaden ten23 health's offering to also process bulk containers (vials), both in liquid and lyophilized form, with two large-scale freeze-driers, each at 12.5 square meters of shelf-space for clinical and commercial use.

ten23 health continues to hire additional colleagues to support the new production lines.

A unique feature of the new facility is photovoltaic façade, covering the complete building exteriors, and being able to provide 45'000 kW per year. ten23 health's facilities in Basel and Visp already operate with 100% renewable energy, consistent with our commitment for the planet.

Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health, commented: *"The completion of the initial phase of construction is a major milestone for ten23 health, our customers and their patients, and towards providing a significant amount of capacity for commercial and clinical sterile medicines for patients. In addition to securing renewable energy for the facility, we are investing in photovoltaics across the whole façade. We are excited to continue building ten23 health into a leading sustainable contract development and manufacturing worldwide."*

About ten23 health

ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Swissfillon, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly-owned subsidiary of ten23 health. ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called the Avogadro constant and equals $6.022 \cdot 10^{23}$. The world is built from small units, and not a homogeneous mass.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health; +41 27 948 90 90

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021